
News|Articles|October 26, 2012
FDA approves Synribo for chronic myelogenous leukemia
FDA has approved omacetaxine mepesuccinate (Synribo, Teva) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease. An estimated 5,430 people will be diagnosed with CML in 2012, according to the National Institutes of Health. Synribo is intended to be used in patients whose cancer progressed after treatment with at least 2 drugs from a class called tyrosine kinase inhibitors (TKIs), also used to treat CML.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Keytruda shows survival edge over Tecentriq, Opdivo in older patients with lung cancer
2
Two studies underscore need for more effective, bladder-sparing therapies in high-risk cancer
3
COVID-19 vaccines could help tumors respond better to immune checkpoint inhibitors
4
Gilead’s Single-Tablet HIV Regimen Meets Primary Endpoints
5

















































